



## FINANCIAL TEAR SHEET

### CORPORATE PROFILE

We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.

### STOCK MARKET DATA

#### ERYP.PA (Common Stock)

<b>Exchange</b>	Paris (Euro)
<b>Price</b>	<b>€26.35</b>
<b>Change (%)</b>	<b>▲ 0.51 (1.97%)</b>
<b>Volume</b>	57,071
<b>52 Week Low</b>	€11.50
<b>Market Cap</b>	€222,420,545
<b>Rolling EPS</b>	-3.20
<b>PE Ratio</b>	0

**Shares Outstanding** 8,732,648

Data as of 10/19/17 3:40 p.m. ET



## RECENT NEWS & EVENTS

	Date	Title
10-Oct-2017 ERYTECH Announces Resubmission of European Marketing Authorization Application for GRASPA in Acute Lymphoblastic Leukemia (phoenix.zhtml?c=254271&p=irol-newsArticle&ID=2305550)	11/13/17	<b>Third Quarter 2017 Financial Results and Business Update: Press Release: Monday, November 13, 2017 (after market)</b>
06-Oct-2017 ERYTECH Files Registration Statement for Proposed Initial Public Offering in the United States (phoenix.zhtml?c=254271&p=irol-newsArticle&ID=2305243)	11/14/17 3:00 p.m. CET	<b>Third Quarter 2017 Financial Results and Business Update: Conference Call (phoenix.zhtml?c=254271&amp;p=irol-EventDetails&amp;EventId=5247802)</b>
06-Oct-2017 Erytech: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –September 30, 2017 (phoenix.zhtml?c=254271&p=irol-newsArticle&ID=2305190)		

## SEC FILINGS

### Filing Date Form

10/10/17	F-6 POS (phoenix.zhtml?c=254271&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9vc
10/06/17	F-1 (phoenix.zhtml?c=254271&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9vdXRsa
12/22/15	D (phoenix.zhtml?c=254271&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9vdXRsa
01/09/15	EFFECT (phoenix.zhtml?c=254271&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9vc